Dr Reddy's CEO proposes $6.54M share sale

The securities listed for sale were acquired through stock options on October 28, 2025.

Available on EDGAR 11/02/2026 - 12:25 PM EST Accepted by SEC EDGAR 11/02/2026 - 12:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Dr Reddy's Laboratories Ltd (RDY) identifies CEO Erez Israeli in a notice proposing the sale of 460,726 sponsored ADRs, with an aggregate market value of $6,542,310. Merrill Lynch is named as broker, October 29, 2026 is the approximate sale date, and NYSE is listed as the exchange.

Key Figures

Sponsored ADRs proposed for sale: 460,726 sponsored ADRs Aggregate market value: $6,542,310 Securities outstanding: 834,640,000 units +1 more

4 metrics

Sponsored ADRs proposed for sale 460,726 sponsored ADRs Proposed sale for Erez Israeli

Aggregate market value $6,542,310 Securities proposed for sale

Securities outstanding 834,640,000 units Issuer securities-information count

Approximate sale date October 29, 2026 Proposed sale

Key Terms

Sponsored ADR, Rule 144, Stock options

3 terms

Sponsored ADR financial

"RDY (DR REDDYS LABORATORIES LTD SPONSORED ADR)"

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock options financial

"STOCK OPTIONS"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RDY sponsored ADRs does Erez Israeli propose to sell?

The notice lists a proposed sale of 460,726 sponsored ADRs with an aggregate market value of $6,542,310.

How were the securities in the RDY sale notice acquired?

The securities-to-be-sold details list stock options as the nature of acquisition and October 28, 2025 as the acquisition date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001986204
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DR REDDYS LABORATORIES LTD
SEC File Number	001-15182
Address of Issuer	600 COLLEGE ROAD EAST PRINCETON NEW JERSEY 08540
Phone	6093759900
Name of Person for Whose Account the Securities are To Be Sold	EREZ ISRAELI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
RDY (DR REDDYS LABORATORIES LTD SPONSORED ADR)	MERRILL LYNCH 75 ROCKEFELLER PLAZA, FLOOR 6 NEW YORK NY 10019	460726	6542310	834640000	10/29/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
RDY (DR REDDYS LABORATORIES LTD SPONSORED ADR)	10/28/2025	STOCK OPTIONS	N/A			460726	10/28/2026	STOCK OPTIONS

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	ASHISH MATHUR
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)